Statera Biopharma Probability of Future Pink Sheet Price Finishing Over 0.0361
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Statera |
Statera Biopharma Target Price Odds to finish over 0.0361
The tendency of Statera Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.04 | 90 days | 0.04 | about 90.79 |
Based on a normal probability distribution, the odds of Statera Biopharma to move above the current price in 90 days from now is about 90.79 (This Statera Biopharma probability density function shows the probability of Statera Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Statera Biopharma has a beta of -1.59. This usually implies as returns on its benchmark rise, returns on holding Statera Biopharma are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Statera Biopharma is expected to outperform its benchmark. Additionally Statera Biopharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Statera Biopharma Price Density |
| Price |
Predictive Modules for Statera Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Statera Biopharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Statera Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Statera Biopharma is not an exception. The market had few large corrections towards the Statera Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Statera Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Statera Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.16 | |
β | Beta against Dow Jones | -1.59 | |
σ | Overall volatility | 0.04 | |
Ir | Information ratio | -0.13 |
Statera Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Statera Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Statera Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Statera Biopharma is not yet fully synchronised with the market data | |
| Statera Biopharma has some characteristics of a very speculative penny stock | |
| Statera Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K. | |
| Statera Biopharma currently holds about 506.1 K in cash with (28.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of Statera Biopharma outstanding shares are owned by corporate insiders |
Statera Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Statera Pink Sheet often depends not only on the future outlook of the current and potential Statera Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Statera Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.1 M | |
| Cash And Short Term Investments | 2 M |
Statera Biopharma Technical Analysis
Statera Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Statera Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Statera Biopharma. In general, you should focus on analyzing Statera Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Statera Biopharma Predictive Forecast Models
Statera Biopharma's time-series forecasting models is one of many Statera Biopharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Statera Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Statera Biopharma
Checking the ongoing alerts about Statera Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Statera Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Statera Biopharma is not yet fully synchronised with the market data | |
| Statera Biopharma has some characteristics of a very speculative penny stock | |
| Statera Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K. | |
| Statera Biopharma currently holds about 506.1 K in cash with (28.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of Statera Biopharma outstanding shares are owned by corporate insiders |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |